Dan Shao1, Qiang Gao2, Xu-Wei Tian3, Si-Yun Wang1, Chang-Hong Liang4, Shu-Xia Wang5. 1. Guangdong General Hospital, Guangdong Academy of Medical Sciences, Department of PET Center, Guangzhou, China. 2. Guangzhou First People's Hospital, Department of Radiology, Guangzhou, China. 3. The First People's Hospital of Kashi, Department of Radiology, Kashi, China. 4. Guangdong General Hospital, Guangdong Academy of Medical Sciences, Department of Radiology, Guangzhou, China. Electronic address: 312368517@qq.com. 5. Guangdong General Hospital, Guangdong Academy of Medical Sciences, Department of PET Center, Guangzhou, China. Electronic address: wang_shuxia@163.com.
Abstract
OBJECTIVES: The purpose of this study was to evaluate the differential diagnostic value of 18F-fluorodeoxy glucose positron emission tomography/computed tomography (18F-FDG PET/CT) for benign and malignant testicular lesions. METHODS: The PET/CT scans of 53 patients with testicular lesions confirmed by biopsy or surgical pathology were retrospectively analyzed. There were 32 cases of malignant tumors and 21 cases of benign lesions. Differences in the maximum standardized uptake value (SUVmax) measurements and the SUVmax lesion/background ratios between benign and malignant lesions were analyzed. The diagnostic value of this PET/CT modality for the differential diagnosis of benign versus malignant testicular lesions was calculated. RESULTS: The differences in the SUVmax measurements and the SUVmax lesion/background ratios between benign and malignant lesions were statistically significant (SUVmax: Z=-4.295, p=0.000; SUVmax lesion/background ratio: Z=-5.219, p=0.000); specifically, both of these indicators were higher in malignant lesions compared to benign lesions. An SUVmax of 3.75 was the optimal cutoff value to differentiate between benign and malignant testicular lesions. The diagnostic sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of this PET/CT modality in the differential diagnosis of benign versus malignant testicular lesions were 90.6%, 80.9%, 86.8%, 87.9%, and 85.0%, respectively. CONCLUSIONS: 18F-FDG PET/CT can accurately identify benign and malignant testicular lesions.
OBJECTIVES: The purpose of this study was to evaluate the differential diagnostic value of 18F-fluorodeoxy glucose positron emission tomography/computed tomography (18F-FDG PET/CT) for benign and malignant testicular lesions. METHODS: The PET/CT scans of 53 patients with testicular lesions confirmed by biopsy or surgical pathology were retrospectively analyzed. There were 32 cases of malignant tumors and 21 cases of benign lesions. Differences in the maximum standardized uptake value (SUVmax) measurements and the SUVmax lesion/background ratios between benign and malignant lesions were analyzed. The diagnostic value of this PET/CT modality for the differential diagnosis of benign versus malignant testicular lesions was calculated. RESULTS: The differences in the SUVmax measurements and the SUVmax lesion/background ratios between benign and malignant lesions were statistically significant (SUVmax: Z=-4.295, p=0.000; SUVmax lesion/background ratio: Z=-5.219, p=0.000); specifically, both of these indicators were higher in malignant lesions compared to benign lesions. An SUVmax of 3.75 was the optimal cutoff value to differentiate between benign and malignant testicular lesions. The diagnostic sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of this PET/CT modality in the differential diagnosis of benign versus malignant testicular lesions were 90.6%, 80.9%, 86.8%, 87.9%, and 85.0%, respectively. CONCLUSIONS: 18F-FDG PET/CT can accurately identify benign and malignant testicular lesions.
Authors: Ciara Conduit; Thuan Tzen Koh; Michael S Hofman; Guy C Toner; Jeremy Goad; Nathan Lawrentschuk; Keen-Hun Tai; Jeremy H Lewin; Ben Tran Journal: Cancer Imaging Date: 2022-10-08 Impact factor: 5.605